Clinical trials confirmed that the applicability of radioiodine to treat non-thyroidal neoplasms was hampered by the heterogenous NIS expression within lesions, resulting in a reduced capacity of such tumors to accumulate 131I [22, 23]. The gene discussed is SLC5A5; the disease is thyroid tumor.